Cargando…

Molecular and functional characterization of a new 3′ end KIT juxtamembrane deletion in a duodenal GIST treated with neoadjuvant Imatinib

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs express the receptor tyrosine kinase KIT, and the majority of GISTs present KIT gain-of-function mutations that cluster in the 5′ end of the receptor juxtamembrane domain. On the other...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perfetti, Vittorio, Laurini, Erik, Aulić, Suzana, Fermeglia, Maurizio, Riboni, Roberta, Lucioni, Marco, Dallera, Elena, Delfanti, Sara, Pugliese, Luigi, Latteri, Francesco Saverio, Pietrabissa, Andrea, Pricl, Sabrina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5593551/ https://www.ncbi.nlm.nih.gov/pubmed/28915580 http://dx.doi.org/10.18632/oncotarget.19341

Ejemplares similares

Unchain My Blood: Lessons Learned from Self-Assembled Dendrimers as Nanoscale Heparin Binders
por: Marson, Domenico, et al.
Publicado: (2019)

Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled in Silico-Experimental Studies. Part II: Self-Assembled siRNA Nanocarriers
por: Laurini, Erik, et al.
Publicado: (2019)

Evolution from Covalent to Self-Assembled PAMAM-Based Dendrimers as Nanovectors for siRNA Delivery in Cancer by Coupled In Silico-Experimental Studies. Part I: Covalent siRNA Nanocarriers
por: Marson, Domenico, et al.
Publicado: (2019)

Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex
por: Laurini, Erik, et al.
Publicado: (2020)

Perceptions and Misconceptions in Molecular Recognition: Key Factors in Self-Assembling Multivalent (SAMul) Ligands/Polyanions Selectivity
por: Marson, Domenico, et al.
Publicado: (2020)

Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence
por: Laurini, Erik, et al.
Publicado: (2021)

Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies
por: Laurini, Erik, et al.
Publicado: (2021)

Metastatic duodenal GIST: role of surgery combined with imatinib mesylate
por: Mohiuddin, Kamran, et al.
Publicado: (2007)

Dichloro-Phenyl-Benzotriazoles: A New Selective Class of Human Respiratory Syncytial Virus Entry Inhibitors
por: Piras, Sandra, et al.
Publicado: (2019)

Reintroduction of Imatinib in GIST
por: Reid, T.
Publicado: (2013)

Large duodenal GIST with massive liver secondaries melting under Imatinib: a case report
por: Sankar, S, et al.
Publicado: (2008)

Dramatic regression and bleeding of a duodenal GIST during preoperative imatinib therapy: case report and review
por: Hecker, Andreas, et al.
Publicado: (2010)

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016)

Imatinib treatment for gastrointestinal stromal tumour (GIST)
por: Lopes, Lisandro F, et al.
Publicado: (2010)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

Unraveling the Mechanisms of Sensitivity to Anti-FGF Therapies in Imatinib-Resistant Gastrointestinal Stromal Tumors (GIST) Lacking Secondary KIT Mutations
por: Boichuk, Sergei, et al.
Publicado: (2023)

Duodenal GIST: a single center experience
por: Beham, Alexander, et al.
Publicado: (2012)

Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H
por: Revheim, Mona-Elisabeth, et al.
Publicado: (2013)

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study
por: Vincenzi, Bruno, et al.
Publicado: (2022)

Imatinib plasma levels: correlation with clinical benefit in GIST patients
por: Widmer, N, et al.
Publicado: (2010)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib
por: Quek, Richard, et al.
Publicado: (2010)

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma
por: Klug, Lillian R., et al.
Publicado: (2018)

Cutaneous mastocytosis with a mutation in the juxtamembrane domain of c-kit in a young laboratory beagle dog
por: Kato, Yuki, et al.
Publicado: (2015)

Antitumor Effect of the Tyrosine Kinase Inhibitor Nilotinib on Gastrointestinal Stromal Tumor (GIST) and Imatinib-Resistant GIST Cells
por: Sako, Hiroyuki, et al.
Publicado: (2014)

Improved Efficacy of First-Line Imatinib in Advanced Gastrointestinal Stromal Tumors (GIST): The Dutch GIST Registry Data
por: Mohammadi, Mahmoud, et al.
Publicado: (2023)

Gastrointestinal Stromal Tumor: GIST Another Duodenal Ulcer
por: Harris, Patrick S., et al.
Publicado: (2020)

Secondary KIT mutations: the GIST of drug resistance and sensitivity
por: Napolitano, Andrea, et al.
Publicado: (2019)

Tumor Volume as an Alternative Response Measurement for Imatinib Treated GIST Patients
por: Schiavon, Gaia, et al.
Publicado: (2012)

Subcapsular Liver Hematoma in Metastatic GIST Complicating Imatinib (Gleevec) Therapy
por: Shankar, Sridhar
Publicado: (2015)

Imatinib-induced Ototoxicity in a Patient with Gastrointestinal Stromal Tumor (GIST)
por: Wasif, Komal, et al.
Publicado: (2016)

Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?
por: Zhuang, Wei, et al.
Publicado: (2018)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Progressing Vulvar Melanoma Caused by Instability in cKIT Juxtamembrane Domain: A Case Report and Review of Literature
por: Englert-Golon, Monika, et al.
Publicado: (2022)

Solitary Intra-abdominal Tuberculous Lymphadenopathy Mimicking Duodenal GIST
por: Kim, You Sun, et al.
Publicado: (2005)

Prognosis and predictive value of KIT exon 11 deletion in GISTs
por: Bachet, J-B, et al.
Publicado: (2009)

Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis
por: Ke, Hengning, et al.
Publicado: (2016)

Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS pathway wild-type GIST)
por: Nannini, Margherita, et al.
Publicado: (2014)

Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)
por: Spitaleri, Gianluca, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lvorj0abvdp1hh78seolj2u9ls